Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

Pulmocide recently completed a Phase 2 safety and tolerability clinical trial (OPERA-S study) in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary ...